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The etiological origin of type 2 diabetes mellitus (T2DM) has long been controversial. The body of literature related to T2DM
is vast and varied in focus, making a broad epidemiological perspective diﬃcult, if not impossible. A data-mining approach was
used to analyze all electronically available scientiﬁc literature, over 12 million Medline records, for “objects” such as genes, diseases,
phenotypes,andchemicalcompoundslinkedtootherobjectswithintheT2DMliteraturebutwerenotthemselveswithintheT2DM
literature. The goal of this analysis was to conduct a comprehensive survey to identify novel factors implicated in the pathology of
T2DM by statistically evaluating mutually shared associations. Surprisingly, epigenetic factors were among the highest statistical
scores in this analysis, strongly implicating epigenetic changes within the body as causal factors in the pathogenesis of T2DM.
Further analysis implicates adipocytes as the potential tissue of origin, and cytokines or cytokine-like genes as the dysregulated
factor(s) responsible for the T2DM phenotype. The analysis provides a wealth of literature supporting this hypothesis, which—if
true—represents an important paradigm shift for researchers studying the pathogenesis of T2DM.
INTRODUCTION
The biomedical literature is vast and growing rapidly,
with approximately 12.7 million records in Medline at the
time of this writing and growing at a rate of 500000 new
records per year. Time and interest are natural limitations
we all share in our awareness of past publications and in
keeping up with current ones. As such, our perspective is
limited and there is an increasing need for computational
methods of literature analysis to gain a broader perspec-
tive[1]—particularlyonesthatleadresearcherstoreason-
able hypotheses that they may not have been able to arrive
at independently [2, 3].
Recently,amethodwasdevelopedforafull-scaleanal-
ysis of Medline records, with the intention of enabling
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software to take over some of this tedium so that a global
analysis of literature trends could be conducted and sta-
tistically relevant associations brought to the attention of
the user [4, 5]. This software package, entitled IRIDES-
CENT (Implicit Relationship IDEntiﬁcation by in-Silico
Construction of an Entity-based Network from Text),
“reads” Medline to identify both the primary names (eg,
“type 2 diabetes”) and synonyms (eg, “adult-onset dia-
betes”) of diseases, genes, phenotypes, and chemical com-
pounds (collectively referred to as “objects”) as they ap-
pear together within Medline titles and abstracts. As ob-
jectsappeartogethermorefrequentlyinthesameMedline
records, their relationship strength is deemed to increase.
After processing all of Medline, this database reﬂects a
historical record of research and a summary of what is
known or, at least, published. Given an object of interest
such as type 2 diabetes mellitus (T2DM), IRIDESCENT
ﬁrst identiﬁes all related objects and then uses these ob-
jects to identify implied relationships (Figure 1). That is,
it identiﬁes new objects that are unrelated to T2DM yet
share many relationships with T2DM. Each of these new
objects shares a set of relationships with the original ob-
ject of interest, but is not itself related. Each set of shared
relationships is ranked against a random network model
for its statistical relevance. These implicitly related objects
identiﬁed by the system have the potential to oﬀer insight2005:2 (2005) Is Type 2 Diabetes Epigenetic? 105
Table 1. A nonexhaustive list of SNP studies that have reported ﬁnding a “signiﬁcant” association between one or more SNPs and
a cohort of T2DM patients. NCBI’s sequence viewer was used to obtain ﬂanking sequence. a denotes PMID = PubMed ID of paper
publishing the SNP. b denotes that C allele was also present. c means that no dbSNP entry was found in exact map position as given,
but the closest dbSNP entries had the same alleles as published, so these were used instead.
Gene Chr Region Mutation Position CpG? PMIDa Sequence dbSNP
IDE 10q23 3  UTR multiple — — 12765971 — —
GFPT2 2p13 3  UTR multiple — — 14764791 — —
IsI-1 5q11.2 5  UTR A→G −47 — 11978668 — —
KIR6.2 11p15.1 Coding E23K — — 12643262 — —
SUR1 11p15.1 Coding G→A 3819 — 11030411 — —
PLA2G4A 1q25 Coding F479L — — 12765847 — —
PTP-1B 20q13.1 Coding C→T 981 — 11836311 — —
GFPT2 2p13 Coding I471V — — 14764791 — —
PPARG2 3p25 Coding P12A — — 12829658 — —
GLUT2 3q26.1 Coding A→G 103 — 12017192 — —
PGC-1 4p15.1 Coding G482S — — 12606537 — —
NR3C1 5q31 Coding A→G 1220 — 12864802 — —
Syntaxin 1A 7q11.23 Coding T→C 204 — 11719842 — —
PRKCZ 1p36.33 Intron G→A — — 12970910 — rs436045
CAPN10 2q37.3 Intron G→A — — 14730479 — SNP43
UCP2 11q13 Promoter G→A −866 Yb 12915397 CTGAGGCGT rs659366
Resistin 19p13.3 Promoter C→G −180 Y 12829623 AAGACGGAG rs1862513
CRP 1q21 Promoter C→T −700 Y 12618085 AACACGCGG SNP133552
PTGS2 1q25.2 Promoter C→G −766 Y 12920574 TCCCGCCTC rs20417
PCK1 20q13.31 Promoter C→G −232 Yc 14764811 CAACCTTGT rs6025628
GLUT2 3q26.2 Promoter A→C −269 N 12017192 AATCACATG None
APM1 3q27 Promoter A→G −11426 Yc 14749263 TCTCGGCTC rs12631446
APM1 3q27 Promoter C→G −11377 Nc 14749263 ATTACAGGT rs10937272
TNF-alpha 6p21.3 Promoter G→A −308 Nc 12818408 CATGGGGA rs1800629
IL-6 7p21 Promoter G→C −174 Y 12589429 TTGCCATGC rs1800795
into novel mechanisms of disease etiology and drug ac-
tion, among other things. We have applied IRIDESCENT
to the study of noninsulin-dependent diabetes mellitus
(NIDDM),morecommonlyknownasT2DM,inthehope
of elucidating novel relationships pertinent to its patho-
genesis.
T2DM is an increasingly prevalent disease in the
world, especially the United States, where the number
of new patients grew 49% between 1991 and 2000. The
economic cost of T2DM is staggering, with the Cen-
ter for Disease Control estimating costs at $132 bil-
lion annually (May 2003 estimates) and aﬀecting more
than 6% of the population in the United States (http://
www.cdc.gov/diabetes/pubs/estimates.htm). Many fac-
tors that correlate with the risk of developing T2DM
have been identiﬁed, but causality has proven elusive.
T2DM has consequently been termed a “complex” disor-
der[6],thoughttobearesultofacomplexinteractionbe-
tween environmental inﬂuence and genetic background.
Alargenumberofstudiessofarhavefocuseduponsingle-
nucleotide polymorphisms (SNPs), the hypothesis being
thatwhiletheirindividualassociationsareweak,theymay
be acting synergistically and possibly in concert with en-
vironmental inﬂuences. Table 1, for example, is a nonex-
haustive list of 25 diﬀerent SNPs reported to have “signiﬁ-
cant” associations with T2DM obtained from a PubMed
query on the words “(type 2 diabetes or NIDDM) and
polymorphism.” The odds any one person would inherit
even a signiﬁcant fraction of these 25, much less than all
of them, are extremely low (allele frequencies aside, note
their distributions across chromosomes). Thus far, little
attention has been paid to the hypothesis that T2DM may
be epigenetic in origin, but this is changing as researchers
realize that traditional theories on complex disease etiol-
ogy are lacking [7].
DNA methylation is a fundamentally important phe-
nomenon within eukaryotes, serving as a means to distin-
guish host DNA from foreign DNA, to determine which
strandofDNAisnewlyreplicated[8]andtoprovideasig-
nal for chromatin condensation such that transcriptional
programs can be inactivated, a process especially impor-
tant during normal development [9]. Loss of methyla-
tion in regulatory DNA regions has been an active re-
search area in cancer, with a number of genes known to106 J. D. Wren and H. R. Garner 2005:2 (2005)
Figure 1. Identifying new relationships that are potentially
implicit from known relationships. IRIDESCENT’s method of
analysis begins with a primary object of interest such as T2DM
(black node) and then identiﬁes all co-citations with other ob-
jects (gray nodes) observed within Medline. IRIDESCENT then
examines all these directly related (gray) nodes in turn for their
relationshipswithotherobjects(whitenodes)thatarenotthem-
selves related to the primary object. Once all of Medline is an-
alyzed and all implicit relationships (white nodes) are identi-
ﬁed, all relationships they share (gray nodes) with the primary
node are individually scored for their statistical signiﬁcance of
co-occurrence and collectively scored for statistical signiﬁcance
against a random network model.
be dysregulated from a loss of methylation in certain tu-
mors [10]. Erosion of normal DNA methylation patterns
seems to occur in most tissues [11] and is time depen-
dent [12, 13]. Although loss of DNA methylation can be
induced chemically (eg, 5-aza-2’-deoxycytidine) or occur
as a result of nutrient deﬁciency (eg, folate), neither of
these cases likely apply to T2DM patients, so it is not clear
whether other environmental factors could have either a
protective or causative eﬀect with regard to T2DM.
MATERIALS AND METHODS
At the time of this analysis, IRIDESCENT was capable
of recognizing 33534 unique objects within text. A total
of 2105 of these were cataloged as being directly related
to T2DM. IRIDESCENT then analyzed each of these 2105
related objects (schematically illustrated in Figure 1)f o r
their relationships, removing those already in the list of
direct relationships. The resulting list contained objects
indirectly related to T2DM. That is to say, they shared a
large set of relationships with T2DM but were not them-
selves related to it. At the time of analysis, none of these
implicitly related objects were found comentioned with
T2DM in the body of any Medline title or abstract. Each
implicit relationship was then evaluated by IRIDESCENT
based upon the number of relationships it shared with
T2DM, relative strength of each relationship, quality of
therelationships(statisticalprobabilitythateachrelation-
ship is valid), and the probability that the two objects
would share a similar set of relationships by chance, given
the relative abundance of both objects and their shared
intermediates within the network. A total of 1287 rela-
tionships were identiﬁed as being shared by the objects
“methylation” and “T2DM.” Not all of these are neces-
sarily causal, correlative, or even meaningful, but many
are. Collectively, they provide evidence that a relationship
does exist between epigenetic control and T2DM and en-
abled us to develop a more comprehensive theory regard-
ing an epigenetic etiology and pathogenesis of T2DM. We
will limit the discussion of shared relationships to those
we believe are most pertinent (summarized in Figure 2).
RESULTS
IRIDESCENT was used to identify and rank objects
within Medline implicitly related to T2DM and identi-
ﬁed “methylation” and “chromatin” as top scoring hits
(Table 2). Methylation is a fundamentally important phe-
nomenonwithineukaryotesforthedevelopmentandreg-
ulation of cellular processes, including the modiﬁcation
and regulation of proteins, lipids, and DNA [14]. Al-
though the relationships linking T2DM and methylation
may refer to more than just DNA methylation, much of
the discussion here will be focused upon DNA methyla-
tionprimarilybecauseofthestronglinktochromatinand
because of the nature of the relationships explored that
suggestapermanentchangetocellularstateistakingplace
in T2DM as opposed to something caused by a temporary
equilibrium shift in molecular methylation capacity.
IRIDESCENT identiﬁed a number of common phe-
notypes in the onset and pathology of T2DM that are also
shared by diseases associated with a change in methyla-
tion state. These shared relationships oﬀer a perspective
on some of the puzzling properties of T2DM not easily
explained by environmental or genetic mutation models.
Forexample,theonsetofT2DMvaries,butusuallyoccurs
later in life and the probability of aﬄiction generally in-
creases with age. This pattern is also characteristic of epi-
genetic disorders such as aberrant expression of X-linked
genes [15], onset of Huntington’s disease [16], and the
oncogenesis of tumors [17, 18]. Not all late-onset illnesses
are caused by epigenetic changes, but most others share
physical accumulations that are unique to the disease,
such as the accumulation of amyloid precursor proteins
in Alzheimer’s disease [19] or Lewy bodies in Parkinsons
[20]. T2DM is highly correlated with the presence of obe-
sity and advanced glycosylation end products (AGEs), but
neither is a requirement for its development nor unique
to it as a disease. T2DM also varies in its severity, gener-
ally increasing over time. This is a phenotype shared with
some tumors that have undergone methylation changes2005:2 (2005) Is Type 2 Diabetes Epigenetic? 107
Table 2. Objects linked to T2DM solely by virtue of relationships they share within Medline. At the time of analysis, none of these
objects were documented in Medline to have a relationship with T2DM (shown at top as a positive control for the query). The
nature of each of these implicit relationships varies and must be determined by examination of the intermediate connections. The
expected value represents how many shared relationships would be expected given a randomly connected network of relationships
with the same properties of the literature-derived one. The quality score represents a statistical weighting of co-mention frequency to
reﬂect conﬁdence that the relationship is not of a trivial nature. The observed to expected ratio (Obs/exp) provides a ranking of how
statistically exceptional any given set of shared relationships is.
Rank Shared relationships Implicit relationship Quality Expect Obs/exp
— 2105 T2DM 1421 329 4.32
1 1361 Endotoxin 1054 308 3.42
2 1312 Hydrocortisone 991 296 3.35
3 1301 Neuroblastoma 975 339 2.88
4 1287 Methylation 959 346 2.77
5 1256 Chromatin 938 339 2.77
NIDDM
MTHFR
Maternal inﬂuence
Fatty acids
Obesity
Cytokines
Homocysteine
Variable severity
Late onset
Methylation
Figure 2. Important relationships shared by methylation and T2DM (referred to as “NIDDM” in the system). A total of
1287 co-cited objects were identiﬁed between the two, about 959 of these reﬂect actual relationships of a nontrivial nature.
Only relationships emphasized within this report are shown here. A full list is available online at http://innovation.swmed.edu/
IRIDESCENT/NIDDM theory.htm.
in promoter sequences, leading to higher gene expression
and a more aggressive phenotype [17]. Another interest-
ing observation about T2DM is the “maternal eﬀect” in
which T2DM patients report a higher frequency of ma-
ternal history of diabetes [21]. While this is not without
controversy [22], such an eﬀect could be explained if de
novo methylation of DNA sequences during development
was due to maternal inﬂuence. This type of phenomenon,
in fact, has been observed in mice [23, 24].
METABOLIC CHANGES IN T2DM
IRIDESCENT also identiﬁed a number of metabolic
alterations in the body’s ability to methylate DNA that
correlatewiththeexistenceoforpredispositiontoT2DM.
For example, elevated levels of homocysteine have been
foundinT2DMpatients,correlatingwithincreasedsever-
ity of the disease as deﬁned by mortality [25]. Homo-
cysteine is a critical metabolic intermediate responsi-
ble for carrying out methylation reactions, and the ele-
vated serum levels of it are also correlated with DNA hy-
pomethylation [26]. It has also been reported that sulfur-
poor diets that force synthesis of cysteine from methion-
ine predispose individuals to type 2 diabetes later in life
[27, 28]. Since methionine aﬀects S-adenosyl methionine
(SAM), which is the methyl donor for the methylation of
newly synthesized DNA, these individuals develop with
an impaired ability to establish de novo DNA methyla-
tion patterns. Genetic factors that lead to deﬁciencies in
the methylation pathway have also been shown to pre-
dispose individuals to develop T2DM. There is a well-
known polymorphism (C677T) in the methylenetetrahy-
drofolate reductase (MTHFR) gene that decreases its eﬃ-
ciency, leading to a global hypomethylation of DNA [29].
Individuals with this mutation are also predisposed to de-
velop T2DM and other complications of the metabolic
syndrome [30]. It has also been found that lowering
the amount of dietary methyl-providing compounds108 J. D. Wren and H. R. Garner 2005:2 (2005)
provided to mice during pregnancy leads to a global hy-
pomethylation of DNA in their oﬀspring and a corre-
sponding modiﬁcation of oﬀspring hair coat color (in-
creased yellow versus agouti). Expression of this yellow
coatcolorisassociatedwithincreasedrisksofobesity,dia-
betes, and cancer [24]. And ﬁnally, it has also been shown
that aberrant methylation patterns have been shown to
induce diabetic symptoms in another form of diabetes,
transient neonatal diabetes mellitus (TNDM), which is a
result of genetic imprinting [31] .T h es a m ei m p r i n t e dr e -
gion responsible for TNDM, however, is not known to be
responsible for T2DM [32].
A number of these metabolic correlations were very
recently noted independently of our own analysis by a
company proposing to do a genome-wide scan for alter-
ations in DNA methylation patterns [33], giving further
credence to the idea that changes in DNA methylation is
a causative factor in the etiology of T2DM. While iden-
tifying an etiology is important, even in general terms,
perhaps equally or more important is elucidating the
causative factors in the pathogenesis of T2DM. If epige-
netic alterations are responsible for T2DM, then at least
three questions naturally arise: ﬁrst, what secreted factors
are responsible for the T2DM phenotype; second, what
tissue type(s) is responsible for expressing the factors that
induce the T2DM phenotype; and third, what environ-
mentalfactorscouldleadtoalossofmethylationandcon-
sequent dysregulation of the secreted factors.
CAUSAL FACTOR ANALYSIS
A possible answer for the ﬁrst question above comes
from the highest scoring object on IRIDESCENT’s list
of implicitly related objects (Table 2): endotoxins. While
endotoxins are not known to be associated or causal in
T2DM, they have been shown to induce obesity and in-
sulin resistance [34]. Most of the relationships shared be-
tween T2DM and endotoxins are objects that either af-
fect or are involved in the immune response, especially
cytokines and inﬂammatory factors. Expression of acute-
phase markers such as C-reactive protein (CRP), and
proinﬂammatorycytokinessuchasIL-6andTNF-alphais
highly correlated with the presence and severity of T2DM
symptoms [35, 36]. These proinﬂammatory cytokines are
also positively correlated with obesity [37]. Furthermore,
TNF-alpha has been found to induce insulin resistance
[38]. Indeed, there is a growing body of evidence that cy-
tokines, more speciﬁcally the proinﬂammatory cytokines,
couldberesponsiblefortheT2DMphenotype.Ithasbeen
observed, for example, that a reversal of T2DM symp-
toms can be induced by disruption of the inﬂammatory
pathway with high doses of aspirin [39]. Troglitazone,
a widely used medication to treat T2DM, has also been
found to have anti-inﬂammatory properties [40], and
the lifestyle changes of exercise and dietary changes pre-
scribed to T2DM patients that have been successful in re-
versing T2DM phenotypes have also been associated with
decreases in inﬂammatory cytokines [41, 42].
If a gene(s) were to be dysregulated, it would likely
happen via demethylation of its (or their) promoters. It
is possible that some of the SNP association studies may
have been linked to promoters with fewer methylatable
sites. Within the 25 SNP studies that were surveyed ear-
lier, 10 were found within the promoter region. None
of them, however, made the association between the re-
ported SNP and the possibility that the SNP would al-
ter the number of CpGs in the promoter. So to examine
this possibility, we used NCBI’s sequence viewer to obtain
the surrounding sequence for these SNPs. We found that,
of the 10 promoter SNPs, 7 altered the number of CpGs
present within the promoter (see Table 1). Of these 7, 3
were proinﬂammatory cytokines associated with T2DM-
resistin [43], CRP [44], and IL-6 [45]. Interestingly, IL-6
controls both resistin [46] and CRP expression, with the
-174 SNP in IL-6 having been linked to heritably high
CRP levels [47]. No study has been done yet to see if
this IL-6 polymorphism can be linked to resistin levels
as well.
TISSUE OF ORIGIN ANALYSIS
Whereas proinﬂammatory cytokines have been impli-
cated as a causal factor in T2DM, it is known that be-
sides B cells and T cells, adipocytes and endothelial cells
are the only other cell types known to normally produce
cytokines. We see that within T cells, cytokine expres-
sion is determined by DNA methylation patterns [48]a n d
can be altered by demethylating agents [49]. Neither T
cells nor B cells seem a likely candidate since they are not
very metabolically active in their na¨ ıve or memory forms,
and their more active diﬀerentiated forms are relatively
short lived. Adipocytes, however, are the primary repos-
itory for lipids and produce cytokines in proportion to
factors such as their size and surrounding obesity [50].
Interestingly, a study by Benjamin and Jost demonstrated
that short-chain fatty acids (SCFAs) can promote the
demethylation of actively transcribed regions [51]. SCFAs
can also aﬀect chromatin structure by inhibiting HDAC,
causing hyperacetylation of histones [52] and making re-
gions of DNA more accessible to transcription factors.
SCFAs are not normally present in high concentrations
within adipocytes, but are normal metabolic byproducts
of the long-chain fatty acids stored within. Since the rate
of lipolysis within adipocytes is increased in T2DM [53],
and can be induced by factors such as TNF-alpha al-
ready known to be elevated in T2DM [54], this would
have an eﬀect upon the relative concentrations of SC-
FAs within adipocytes. Higher amounts of SCFA metabo-
lites within adipocytes might provide an environment in
which loss of DNA methylation could occur and, coupled
with active transcriptional activity, could lead to the hy-
pomethylationandconsequentdysregulationofcytokines
orcytokine-likefactorsthatleadtoT2DM.Weseesugges-
tive evidence of this in a study by Laimer et al involving
IL-6 and TNF-alpha levels in 20 women before and 1 year
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of other obesity markers such as CRP declined, while IL-6
and TNF-alpha did not [55].
Withintheproposedmodel,theetiologyofT2DMoc-
curs within adipocytes, involving a gradual loss of DNA
methylation around the promoters of cytokines and/or
cytokine-like factors normally secreted by the adipocyte.
This loss of methylation is favored under the conditions
provided by obesity and is caused by transcriptional ac-
tivity. The subsequent loss of methylation leads to dysreg-
ulation of these factors, resulting in a constitutive increase
in the production of cytokines from adipocytes. Negative
regulatory factors decrease the expression of these factors,
enabling management of the T2DM phenotype, but only
as long as they are present.
ETIOLOGICAL MODELS OF T2DM
We examine this new proposed model in the context
of the three dominant models for the etiology and patho-
genesis of T2DM: genetic, environmental, and a complex
interaction of both factors. Genetic studies have shown
that inheritance plays a role in determining an individ-
ual’sriskofdevelopingT2DM[56].Linkagestudies,while
delineating a number of potential susceptibility regions,
have yet to be successful in identifying a speciﬁc gene
or set of genes responsible for the most popular form
of T2DM, despite the large cohorts involved. The well-
established correlation between obesity and T2DM also
indicates that environmental variables aﬀect the patho-
genesis of T2DM. The prevailing “complex disease” the-
oryisthattheonsetofT2DMiscausedbyoneormoreen-
vironmental variables acting upon a genetic background,
of which there may be many contributing genes [6]. This
theory explains how susceptibility to T2DM correlates
with genetic background, such as race, as well as with en-
vironmental variables such as diet and exercise. But there
are at least two observations about the nature of T2DM
that the complex disease model does not explain while
the epigenetic model does: time dependency and systemic
memory.
Even when environmental variables are present on a
susceptible genetic background, the onset of T2DM is
still time dependent. That is to say, the risk of develop-
ing T2DM is positively correlated with age. The complex
disease model does not easily explain this except to postu-
late an as-yet-unknown “trigger” event, such as an infec-
tion. Even if this were true, it would not explain the per-
sistence of T2DM after onset. T2DM is diagnozed by the
levels of insulin resistance and glucose intolerance expe-
rienced by a patient, levels which can be altered to pre-
diabetic levels by suﬃcient changes in lifestyle. T2DM,
however, cannot be reversed [57]. None of the existing
models account for a mechanism by which the body can
“remember” its state. The methylation status of genes,
however, is intended to be a relatively persistent phe-
nomenon, responsible for committing cells into their dif-
ferentiated states [58]. Given that loss of DNA methyla-
tioniscorrelatedwithage[59],thatthenumberofmethy-
lated sites in a genome is determined by inheritance, and
that loss of methylation can be aﬀected by environmen-
tal variables, the proposed epigenetic model merits seri-
ous consideration. An excellent review was recently pub-
lished, contrasting the properties of epigenetic disorders
with the other models of disease etiology discussed here
[60].
DISCUSSION
Contrary to the mutation-centric model, which as-
sumes alterations in function or activity based upon ei-
ther somatic or inherited mutations in DNA, an epige-
neticmodelimpliesdysregulationofageneorsetofgenes.
Thus, phenotypes resulting from the expression of such
genes would make biological sense under other physi-
ological conditions. Preventing energy inﬂux into cells
by inducing insulin resistance makes sense when consid-
ered within the context of the role of the immune sys-
tem. Acquired immunity in the form of B-cell matura-
tion and antibody production takes time during which
pathogens are able to replicate. Part of the early immune
response consists of an increase in the presence of proin-
ﬂammatory cytokines within the circulating bloodstream
[61, 62]. It would make sense that one role of these early
responders would be to stem the inﬂux of resources like
glucose into cells to prevent their utilization by invad-
ing pathogens. Since adipocytes contain a large reser-
voir of energy, this makes them ideal targets for invading
pathogens and could necessitate their taking a more ac-
tiveroleinﬁghtinginfectionbeyondthatofothersomatic
cells.
Identifying expression changes via microarray analy-
sis and subsequently examining the methylation status of
their promoters can obtain a candidate list for genes that
have undergone epigenetic dysregulation. If this theory is
ultimately shown to be correct, it will allow us the ability
to diagnoze the current level of epigenetic progression to-
wards T2DM in patients and oﬀer hope for a T2DM cure
that could not be easily provided in a mutation-centric
model. It is not apparent how region-speciﬁc methyla-
tion could be reintroduced to aﬀected regions, but since
de novo methylation is a normal process during devel-
opment and certain viruses can “shut oﬀ” the expres-
sion of immune-related genes by hypermethylation, it
stands to reason that the mechanism to do so is already
in place.
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